# Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

> **NCT02769962** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 45 (actual)

## Conditions studied

- Urothelial Carcinoma
- Urothelial Cancer
- Lung Neoplasms
- Small Cell Lung Cancer
- Prostate Cancer

## Interventions

- **DRUG:** EP0057
- **DRUG:** olaparib
- **DIAGNOSTIC_TEST:** CT scan
- **DIAGNOSTIC_TEST:** CT chest, abdomen, and pelvis
- **DIAGNOSTIC_TEST:** Bone scan
- **DIAGNOSTIC_TEST:** ECG
- **DIAGNOSTIC_TEST:** Echocardiogram
- **PROCEDURE:** Biopsy

## Key facts

- **NCT ID:** NCT02769962
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-09
- **Primary completion:** 2023-04-19
- **Final completion:** 2025-03-04
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2025-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02769962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02769962, "Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT02769962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*